

THE PFIZER CLINICAL TRIAL

USADO PARA AUTORIZAR BNT162B2 PARA AUTORIZAÇÃO DE USO DE EMERGÊNCIA

USED TO AUTHORIZE BNT162B2 FOR EMERGENCY USE AUTHORIZATION

CAN WE TRUST THE CLINICAL TRIALS USED TO APPROVE THE COVID-19 VACCINES?

PODEMOS CONFIAR NOS ENSAIOS CLÍNICOS UTILIZADOS PARA APROVAR AS VACINAS CONTRA A COVID-19?

- We have been given various pieces of a puzzle over the last 2 years, and the picture is ALMOST complete
- Recebemos várias peças de um quebra-cabeça nos últimos 2 anos, e a imagem está QUASE completa

WHO DO I REPRESENT - APRESENTAREMOS

- O resultado da revisão dos documentos do Pfizer, obtidos na FDA, devido ao Ato de Liberdade de Informação
- Os documentos foram revisados por mais de 3.250 voluntários, do meio acadêmico e de pesquisas, além especialistas em “clinical trials”.
- Nenhum dos pesquisadores tem qualquer conflito de interesse, tampouco tem ações do laboratório em questão
- Nossas equipes têm reunido os dados da Pfizer divulgados pelo FDA, depois de tentarem ocultá-los por 75 anos
- Our teams have been piecing together the Pfizer data released by the FDA, after they tried to hide it for 75 years

THE PFIZER CLINICAL TRIAL C4591001

- FDA review Dec 11, 2020 to grant EUA
- 43,448 subjects: 21,720 with BNT162b2 and 21,728 with placebo
- Pfizer reported 6 cardiac deaths (2 vaccinated: 4 placebo) claiming 50% reduction in deaths
- A Pfizer relatou 6 cardíaca mortes (2 vacinados: 4 placebo), alegando redução de 50% nas mortes
- Case Report forms show that there were at least 8 deaths at that time (4 vaccinated: 4 placebo) - No reduction in deaths
- Os formulários de relato de caso mostram que houve 8 mortes naquele momento (4 vacinados: 4 placebo) - Sem redução nas mortes

N Engl J Med 2020;383:2603-15

International Journal of Vaccine Theory, Practice, and Research

IJVTPR

Forensic Analysis of the 38 Subject Deaths in the 6-Month Interim Report of the Pfizer/BioNTech BNT162b2 mRNA Vaccine Clinical Trial

Corinne A. Michels, PhD; Daniel Perrier, BSEE; Jeyanthi Kunadhasan, MD; Ed Clark, MSE; Joseph Gehrett, MD; Barbara Gehrett, MD; Kim Kwiatek, MD; Sarah Adams, RN; Robert Chandler, MD; Leah A. Stagno, BS, AAS; Tony Damian CMT, CST, RMT; Erika Delph, RPh; and Chris Flowers, MD

All authors associated with DailyClout Pfizer/BioNTech Documents Investigations Team 3; PO Box 24; Millerton, NY 12546 https://dailyclout.io/; corresponding author: email corinne.michels@icloud.com

International Journal of Vaccine Theory, Practice, and Research 3(1) Page 973
https://doi.org/10.56098/ijvtpr.v3i1.85 Received 5 Sep 2023 published 17 Oct 2023

EM NENHUM MOMENTO DESTE ENSAIO HOUVE INTERVENÇÃO COM A VACINA QUE SALVOU VIDAS

AT NO POINT DURING THIS TRIAL, WAS INTERVENTION WITH THE VACCINE LIFESAVING



International Journal of Vaccine Theory, Practice, and Research 3(1)
https://doi.org/10.56098/ijvtpr.v3i1.85 Received 5 Sep 2023 published 17 Oct 2023

DATA CUT-OFF POINT NOV 14
PONTO DE CORTE DE DADOS 14 DE NOVEMBRO

Examining the table below, which is adapted from the "Forensic Analysis of the 38 Subject deaths in the 6-Month Interim Report of the Pfizer /BioNTech BNT162b2 mRNA Vaccine Clinical Trial" (Michels et al., 2023), reveals that as of the data cut-off date of November 14, 2020, a total of 11 deaths (six deaths in vaccinated arm of the study and five in the placebo arm) were recorded. This stands in contrast to the six deaths publicly disclosed at the VRBPAC meeting and in the Polack article. The capture rate seems to be 33% in the vaccinated arm (two reported deaths out of six) and 80% in the placebo arm (four reported deaths out of five).

Days of delay in recording subject deaths

BNT162b2 arm

Period	Subject ID	Date of Death	Officially Recorded Date (from Clinical Report File)	Delay Recording Death (Days)
#P-C	11621327	13Sept2020	24Sept2020	11
P-C	11141050	19Oct2020	25Nov2020	37
#P-C	10071101	21Oct2020	5Nov2020	15
P-C	11201050	07Nov2020	3Dec2020	26
P-C	11521497	11Nov2020	18Nov2020	7
P-C	10891073	12Nov2020	4Dec2020	22

Placebo arm

Period	Subject ID	Date of Death	Officially Recorded Date (from Clinical Report File)	Delay Recording Death (Days)
#P-C	11521085	26Aug2020	27Aug2020	1
#P-C	12313972	28Sept2020	1Oct2020	3
P-C	11561124	02Nov2020	19Nov2020	17
#P-C	10661350	03Nov2020	10Nov2020	7
#P-C	10811194	04Nov2020	11Nov2020	7

Shaded ==undisclosed at DEC10th VRPBAC meeting

https://dailyclout.io/letter-to-texas-attorney-general-ken-paxton-vaccinated-deaths-in-pfizers-covid-vaccine-clinical-trial-not-disclosed-to-fda-with-eua-data/

DESTRUCTION OF THE PLACEBO GROUP
DESTRUIÇÃO DO GRUPO PLACEBO

- Placebos are used as a control to assure the long term SAFETY of a treatment
- Placebos são usados como controle para garantir a SEGURANÇA de um tratamento a longo prazo
- After the EUA was granted, virtually all the placebos were given the BNT162b2
- Depois que a EUA foi concedida, praticamente todos os placebos receberam o BNT162b2
- There was no longer a Control Group
- Não havia mais um Grupo de Controle
- This also happened in the Pediatric clinical trials
- Isso também aconteceu nos ensaios clínicos pediátricos

CONCLUSIONS

- The vaccine did not
  - Prevent death
  - Was not tested for long - term safety
  - Never studied reducing transmission of the virus

- A vacina não
  - Prevenir a morte
  - Não foi testado para segurança a longo prazo
  - Nunca estudei reduzir a transmissão do vírus

PFIZER PEDIATRIC TRIAL

- 15 de junho de 2022. VRBPAC se reuniu para aprovar vacinas para crianças a partir de 6 meses
- 4.526 crianças em 65 locais de teste
- Mais de 3.000 ‘desistiram antes’ do final do julgamento então apenas um pequeno número poderia ser avaliado

- June 15, 2022. VRBPAC met to approve vaccines for children from 6 months old
- 4526 children at 65 trial sites
- More than 3000 ‘dropped out’ before the end of the trial so only a small number could be evaluated

PFIZER PEDIATRIC TRIAL

- A Pfizer apresentou evidências de que os únicos anticorpos produzidos nas crianças foram para o pico de Wuhan (cepa alfa), sem anticorpos detectáveis para a variante Omicron
- Após 2 meses, 2x mais casos de COVID em vacinados versus placebo

- Pfizer presented evidence that the only antibodies produced in the children were to the Wuhan (alpha strain) spike with no detectable antibodies to the Omicron variant
- After 2 months, 2x more COVID cases in vaccinated vs placebo

Table 19. First COVID-19 Occurrence Any Time After Dose 1, Blinded Follow-Up Period, Participants 6-23 Months of Age, All-Available Efficacy Population, Study C4591007

Efficacy Endpoint	BNT162b2 3 µg (N[a]=1178) Cases, n1[b] Surveillance Time[c], (n2[d])	Placebo (N[a]=598) Cases, n1[b] Surveillance Time[c], (n2[d])	Vaccine Efficacy % (95% CI[e])
First COVID-19 occurrence after Dose 1	98 0.456, (1027)	58 0.232, (524)	14.0 (-21.2, 38.4)
Dose 1 to before Dose 2	13 0.063, (1027)	5 0.032, (524)	-29.7 (-364.7, 56.6)
Dose 2 to <7 days after Dose 2	3 0.019, (1002)	3 0.010, (517)	48.4 (-285.0, 93.1)
≥7 Days after Dose 2 to before Dose 3	80 0.338, (998)	48 0.173, (512)	14.5 (-24.9, 41.0)
Dose 3 to <7 days after Dose 3	1 0.006, (336)	0 0.003, (147)	UND (NA, NA)
≥7 Days after Dose 3	1 0.030, (277)	2 0.015, (139)	75.5 (-370.1, 99.6)

Source: EUA 27034.554 Efficacy 508 tables. Table E.D.1.
Abbreviations: NA=not applicable; VE=Vaccine Efficacy; UND=Undefined.
a. N=number of participants in the specified group.
b. n1=Number of participants meeting the endpoint definition.
c. Total surveillance time in 1,000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from Dose 1 to the end of the surveillance period for the overall row and from start to the end of range stated for each interval.
d. n2=Number of participants at risk for the endpoint.
e. Confidence interval (CI) for VE is derived based on the Clopper and Pearson method adjusted to the surveillance time.

YOUNG CHILDREN DID NOT GET THE ANTIBODIES FROM USING THIS VACCINE

CRIANÇAS PEQUENAS NÃO OBTIVERAM OS ANTICORPOS AO USAR ESTA VACINA

- Children between 2 and 4, failed the 2-dose immuno-bridging goal
- when the antibody titers they generated were compared with the 16-25 age group

(the standard for the Clinical Trial C4591001)

- Crianças entre 2 e 4 anos falharam na meta de ponte imunológica de 2 doses
- quando os títulos de anticorpos gerados foram comparados com a faixa etária de 16 a 25 anos

(o padrão para o Ensaio Clínico C4591001)

QUOTE FROM DR RUBIN (VRBPAC OCT 2022)

Nunca saberemos quão segura é a vacina até começarmos a administrá-la. É assim que acontece



THE VACCINES WERE GIVEN BASED ON BAD EVIDENCE

- As evidências de injeções de COVID em crianças foram muito menores do que as evidências originais fornecidas ao FDA
- Não há evidências de que estes devam ser administrados a crianças, dados os efeitos adversos conhecidos

- Evidence for COVID shots in children was far less than the original evidence supplied to the FDA
- There is no evidence that these should be given to children, given the known adverse effects


There are still missing pieces to this puzzle, yet to be released
Ainda faltam peças neste quebra-cabeça, que ainda não foram lançadas

PUBLICATIONS